The Viral Vectors and Plasmid DNA Manufacturing Market Report 2024-2034: This report will prove invaluable to leading firms striving for new revenue pockets if they wish to better understand the industry and its underlying dynamics. It will be useful for companies that would like to expand into different industries or to expand their existing operations in a new region.
Viral vectors and plasmids are instrumental in the field of biotechnology, especially in the context of advancements like CRISPR-Cas9 gene editing. They serve as indispensable vehicles for delivering genetic material with precision, enabling scientists to manipulate and modify genes for various purposes, from basic research to therapeutic interventions. Viral vectors, such as adeno-associated viruses (AAVs) and lentiviruses, have become central players in gene therapy, allowing for the targeted insertion of genetic material into host cells. Plasmids, on the other hand, are versatile circular pieces of DNA commonly used in molecular biology research to introduce foreign genes into cells or organisms. Their importance extends beyond gene editing to encompass a wide array of biotechnological applications, including vaccine development and protein production.
Recent developments in the biotechnology landscape further underscore the critical role of viral vectors and plasmids. In January 2023, Catalent, a prominent player in the biopharmaceutical industry, inaugurated a state-of-the-art plasmid DNA (pDNA) manufacturing facility in Gosselies, Belgium. This facility not only signifies the growing demand for plasmids but also the need for their efficient production at a commercial scale. Catalent’s commitment to producing off-the-shelf plasmids to support cell and gene companies reflects the broader trend in the industry, where these genetic tools are in high demand. The integration of pDNA expertise in Gosselies with the clinical and commercial production of viral vectors for gene therapy, cell therapy, and mRNA across their network is a strategic move that ensures the continuity of the supply chain. It’s a testament to the interdependence of these elements in the biotechnology ecosystem and their collective role in driving therapeutic innovations.
What Questions Should You Ask before Buying a Market Research Report?
• How is the viral vectors and plasmid DNA manufacturing market evolving?
• What is driving and restraining the viral vectors and plasmid DNA manufacturing market?
• How will each viral vectors and plasmid DNA manufacturing submarket segment grow over the forecast period and how much revenue will these submarkets account for in 2034?
• How will the market shares for each viral vectors and plasmid DNA manufacturing submarket develop from 2024 to 2034?
• What will be the main driver for the overall market from 2024 to 2034?
• Will leading viral vectors and plasmid DNA manufacturing markets broadly follow the macroeconomic dynamics, or will individual national markets outperform others?
• How will the market shares of the national markets change by 2034 and which geographical region will lead the market in 2034?
• Who are the leading players and what are their prospects over the forecast period?
• What are the viral vectors and plasmid DNA manufacturing projects for these leading companies?
• How will the industry evolve during the period between 2024 and 2034? What are the implications of viral vectors and plasmid DNA manufacturing projects taking place now and over the next 10 years?
• Is there a greater need for product commercialisation to further scale the viral vectors and plasmid DNA manufacturing market?
• Where is the viral vectors and plasmid DNA manufacturing market heading and how can you ensure you are at the forefront of the market?
• What are the best investment options for new product and service lines?
• What are the key prospects for moving companies into a new growth path and C-suite?
You need to discover how this will impact the viral vectors and plasmid DNA manufacturing market today, and over the next 10 years:
• Our 408-page report provides 166 tables, 183 charts /graphs exclusively to you.
• The report highlights key lucrative areas in the industry so you can target them – NOW.
• It contains in-depth analysis of global, regional and national sales and growth.
• It highlights for you the key successful trends, changes and revenue projections made by your competitors.
This report tells you TODAY how the Viral Vectors and Plasmid DNA Manufacturing Market will develop in the next 10 years, and in line with the variations in COVID-19 economic recession and bounce. This market is more critical now than at any point over the last 10 years.
Forecasts to 2034 and other analyses reveal commercial prospects
• In addition to revenue forecasting to 2034, our new study provides you with recent results, growth rates, and market shares.
• You will find original analyses, with business outlooks and developments.
• Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges), cost structure, impact of rising viral vectors and plasmid DNA manufacturing prices and recent developments.
This report includes data analysis and invaluable insight into how COVID-19 will affect the industry and your company. Four COVID-19 recovery patterns and their impact, namely, “V”, “L”, “W” and “U” are discussed in this report.
Segments Covered in the Report
Vector Type
• Adenovirus
• Retrovirus
• Plasmid DNA
• AAV
• Lentivirus
• Other Vectors
Application
• Antisense and RNAi
• Gene Therapy
• Cell Therapy
• Vaccinology
End-use
• Pharma and Biopharma Companies
• Research Institutes
Disease
• Oncology
• Genetic Disorders
• Infectious Diseases
• Others Diseases
Workflow
• Upstream
• Downstream
In addition to the revenue predictions for the overall world market and segments, you will also find revenue forecasts for five regional and 24 leading national markets:
North America
• U.S.
• Canada
Europe
• Germany
• UK
• France
• Spain
• Italy
• Sweden
• Switzerland
• Rest of Europe
Asia Pacific
• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Taiwan
• Rest of Asia Pacific
Latin America
• Brazil
• Mexico
• Argentina
• Rest of Latin America
MEA
• GCC
• South Africa
• Rest of MEA
Need industry data? Please contact us today.
The report also includes profiles and for some of the leading companies in the Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034, with a focus on this segment of these companies’ operations.
Leading companies profiled in the report
• Addgene
• Advanced BioScience Laboratories, Inc. (ABL)
• Aldevron
• Altogen Biosystems
• Amicus Therapeutics
• ATUM
• Batavia Biosciences B.V.
• BioNTech IMFS
• Biovian Oy
• bluebird bio Inc.
• Catalent Inc.
• CEVEC Pharmaceuticals GmbH
• Charles River Laboratories
• Creative Biogene
• FUJIFILM Diosynth Biotechnologies
• GENEZEN
• Lonza
• Merck KGaA
• Recipharm AB
• Thermo Fisher Scientific Inc.
• uniQure N.V.
• VGXI Inc.
• Virovek
• VIVEbiotech
• Waisman Biomanufacturing
• WuXi AppTec
• Yposkesi, Inc.
Overall world revenue for viral vectors and plasmid DNA manufacturing market, 2024 to 2034 in terms of value the market will surpass US$1,350 million in 2024, our work calculates. We predict strong revenue growth through to 2034. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
How will the Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034 report help you?
In summary, our 400+ page report provides you with the following knowledge:
• Revenue forecasts to 2034 for Viral Vectors and Plasmid DNA Manufacturing Market, 2024 to 2034, with forecasts for vector types, application, and end-use, disease and workflow each forecast at a global and regional level – discover the industry’s prospects, finding the most lucrative places for investments and revenues.
• Revenue forecasts to 2034 for five regional and 24 key national markets – See forecasts for the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034 market in North America, Europe, Asia-Pacific, Latin America, and MEA. Also forecasted is the market in the US, Canada, Germany, UK, France, Spain, Italy, Sweden, Switzerland, China, India, Japan, Australia, South Korea, Singapore, Taiwan, Brazil, Mexico, Argentina, GCC, South Africa, and among other prominent economies.
• Prospects for established firms and those seeking to enter the market – including company profiles for 27 of the major companies involved in the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034.
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with invaluable business intelligence.
Information found nowhere else
With our new report, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Viral Vectors and Plasmid DNA Manufacturing Market 2024 to 2034, market-leading companies. You will find data, trends and predictions.
To access the data contained in this document please email contactus@visiongain.com
Buy our report today Viral Vectors & Plasmid DNA Manufacturing Market Report 2024-2034: Forecasts by Vector Type (Adenovirus, Retrovirus, Plasmid DNA, AAV, Lentivirus, Others), by Application (Antisense and RNAi, Gene Therapy, Cell Therapy, Vaccinology), by End-use (Pharma and Biopharma Companies, Research Institutes), by Disease (Oncology, Genetic Disorders, Infectious Diseases, Others), by Workflow (Upstream, Downstream) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies AND COVID-19 Impact and Recovery Pattern Analysis. Avoid missing out by staying informed – order our report now.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for a specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: contactus@visiongain.com
1 Report Overview
1.1 Objectives of the Study
1.2 Introduction to Viral Vectors and Plasmid DNA Manufacturing Market
1.3 What This Report Delivers
1.4 Why You Should Read This Report
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report for?
1.7 Methodology
1.7.1 Market Definitions
1.7.2 Market Evaluation & Forecasting Methodology
1.7.3 Data Validation
1.7.3.1 Primary Research
1.7.3.2 Secondary Research
1.8 Frequently Asked Questions (FAQs)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2 Executive Summary
3 Market Overview
3.1 Key Findings
3.2 Market Dynamics
3.2.1 Market Driving Factors
3.2.1.1 Shaping the Future of Rare Disease Treatment with Viral Vector Solutions
3.2.1.2 Viral Vectors and Plasmids Play a Pivotal Role in Enabling Precision and Breakthroughs in Biotechnology
3.2.1.3 Investing in Progress Involves Capitalizing on the Viral Vector Revolution
3.2.2 Market Restraining Factors
3.2.2.1 Low Yields and Individual Optimization Hold Back Downstream Processes
3.2.2.2 Viral Vector Demand Outpaces Capacity Growth Despite Increased Investments
3.2.3 Market Opportunities
3.2.3.1 Seizing the Viral Vector Opportunity for Enhanced Healthcare Access and Cost-efficient Therapies
3.2.3.2 Advances in Genome Sequencing to Fuel Market Growth
3.2.3.3 Rising Demand for Synthetic DNA Templates in RNA Medicine
3.3 COVID-19 Impact Analysis
3.4 Porter’s Five Forces Analysis
3.4.1 Bargaining Power of Suppliers
3.4.2 Bargaining Power of Buyers
3.4.3 Competitive Rivalry
3.4.4 Threat from Substitutes
3.4.5 Threat of New Entrants
3.5 PEST Analysis
4 Viral Vector Production Capacity Mapping Analysis
4.1 CMOs Capacity for Viral Vector Manufacturing
4.2 Cleanroom Suites Facilities: Leading Viral Vector Manufacturers
4.3 Surge of Investments Reshaping Contract Manufacturing Infrastructure.
4.4 Investments and Expansions in CMO/CDMO Facilities in the Cell and Gene Therapy Sector
5 Viral Vector Production & Yield Analysis
5.1 Introduction
5.2 ATMP Vectors and Manufacturing Platforms
5.3 Regulatory Challenges for Viral Vectors for Cell and Gene Therapy
6 Viral Vector Manufacturing: Process Economic Considerations and Challenges
6.1 Technological Advances in Manufacturing
6.2 Stable Producer Cell Lines
6.3 Mitigating the Challenges of Cytotoxicity through Stable Producer Lines
6.4 Key Factors in Process Development for the Utilization of Stable Producer Lines
6.5 Enhancing Efficiency and Lowering Costs: The Contribution of Stable Producer Cell Lines in CGT Production
6.5.1 Simplified Upstream Production
6.5.2 Lower Costs for Reagents and Labour
6.5.3 More Flexibility for Scale Up
6.6 When is the Time to Switch from Transient Transfection to Stable Producer Cell Lines for LVV Manufacturing?
6.7 Cost Considerations
6.8 Regulatory Expectations
7 Challenges and Advances in Recombinant Adeno-Associated Viruses (rAAVs) Gene Therapy Biomanufacturing
7.1 Introduction
8 Viral Vectors Production Process Analysis
8.1 Introduction
8.2 Upstream Unit Operations (Cell Thaw and Expansion Through Transfection)
8.3 Downstream Unit Operations (Harvest Through Purification)
8.4 Formulation/Stability and Fill/Finish
8.5 Viral Analytics
8.6 Viral Vector Production: Facilities Needs
8.7 Regulatory Standard Needs
8.8 Workforce Development and Needs
9 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Vector Type
9.1 Key Findings
9.2 Vector Type Segment: Market Attractiveness Index
9.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
9.4 Adenovirus
9.4.1 Market Size by Region, 2024-2034 (US$ Million)
9.4.2 Market Share by Region, 2024 & 2034 (%)
9.5 Retrovirus
9.5.1 Market Size by Region, 2024-2034 (US$ Million)
9.5.2 Market Share by Region, 2024 & 2034 (%)
9.6 Plasmid DNA
9.6.1 Market Size by Region, 2024-2034 (US$ Million)
9.6.2 Market Share by Region, 2024 & 2034 (%)
9.7 AAV
9.7.1 Market Size by Region, 2024-2034 (US$ Million)
9.7.2 Market Share by Region, 2024 & 2034 (%)
9.8 Lentivirus
9.8.1 Market Size by Region, 2024-2034 (US$ Million)
9.8.2 Market Share by Region, 2024 & 2034 (%)
9.9 Other Vectors
9.9.1 Market Size by Region, 2024-2034 (US$ Million)
9.9.2 Market Share by Region, 2024 & 2034 (%)
10 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Application
10.1 Key Findings
10.2 Application Segment: Market Attractiveness Index
10.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
10.4 Antisense and RNAi
10.4.1 Market Size by Region, 2024-2034 (US$ Million)
10.4.2 Market Share by Region, 2024 & 2034 (%)
10.5 Gene Therapy
10.5.1 Market Size by Region, 2024-2034 (US$ Million)
10.5.2 Market Share by Region, 2024 & 2034 (%)
10.6 Cell Therapy
10.6.1 Market Size by Region, 2024-2034 (US$ Million)
10.6.2 Market Share by Region, 2024 & 2034 (%)
10.7 Vaccinology
10.7.1 Market Size by Region, 2024-2034 (US$ Million)
10.7.2 Market Share by Region, 2024 & 2034 (%)
11 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Disease
11.1 Key Findings
11.2 Disease Segment: Market Attractiveness Index
11.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
11.4 Oncology
11.4.1 Market Size by Region, 2024-2034 (US$ Million)
11.4.2 Market Share by Region, 2024 & 2034 (%)
11.5 Genetic Disorders
11.5.1 Market Size by Region, 2024-2034 (US$ Million)
11.5.2 Market Share by Region, 2024 & 2034 (%)
11.6 Infectious Diseases
11.6.1 Market Size by Region, 2024-2034 (US$ Million)
11.6.2 Market Share by Region, 2024 & 2034 (%)
11.7 Other Diseases
11.7.1 Market Size by Region, 2024-2034 (US$ Million)
11.7.2 Market Share by Region, 2024 & 2034 (%)
12 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by End-use
12.1 Key Findings
12.2 End-use Segment: Market Attractiveness Index
12.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
12.4 Pharma and Biopharma Companies
12.4.1 Market Size by Region, 2024-2034 (US$ Million)
12.4.2 Market Share by Region, 2024 & 2034 (%)
12.5 Research Institutes
12.5.1 Market Size by Region, 2024-2034 (US$ Million)
12.5.2 Market Share by Region, 2024 & 2034 (%)
13 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Workflow
13.1 Key Findings
13.2 Workflow Segment: Market Attractiveness Index
13.3 Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
13.4 Upstream
13.4.1 Market Size by Region, 2024-2034 (US$ Million)
13.4.2 Market Share by Region, 2024 & 2034 (%)
13.5 Downstream
13.5.1 Market Size by Region, 2024-2034 (US$ Million)
13.5.2 Market Share by Region, 2024 & 2034 (%)
14 Viral Vectors and Plasmid DNA Manufacturing Market Analysis by Region
14.1 Key Findings
14.2 Regional Market Size Estimation and Forecast
15 North America Viral Vectors and Plasmid DNA Manufacturing Market Analysis
15.1 Key Findings
15.2 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
15.3 North America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
15.4 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
15.5 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
15.6 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
15.7 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
15.8 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
15.9 North America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
15.10 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Analysis
15.11 Canada Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16 Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.1 Key Findings
16.2 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
16.3 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
16.4 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
16.5 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
16.6 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
16.7 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
16.8 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
16.9 Europe Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
16.10 Germany Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.11 France Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.12 UK Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.13 Italy Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.14 Spain Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.15 Sweden Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.16 Switzerland Viral Vectors and Plasmid DNA Manufacturing Market Analysis
16.17 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.1 Key Findings
17.2 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
17.3 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
17.4 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
17.5 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
17.6 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
17.7 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
17.8 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
17.9 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
17.10 Japan Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.11 China Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.12 India Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.13 Australia Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.14 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.15 Singapore Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.16 Taiwan Viral Vectors and Plasmid DNA Manufacturing Market Analysis
17.17 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Analysis
18 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis
18.1 Key Findings
18.2 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
18.3 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
18.4 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
18.5 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
18.6 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
18.7 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
18.8 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
18.9 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Analysis
18.10 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Analysis
18.11 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Analysis
18.12 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Analysis
19 MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis
19.1 Key Findings
19.2 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
19.3 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Country, 2024, 2029 & 2034 (US$ Million)
19.4 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Country
19.5 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Vector Type
19.6 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Application
19.7 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by End-use
19.8 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Disease
19.9 MEA Viral Vectors and Plasmid DNA Manufacturing Market Size Estimation and Forecast by Workflow
19.10 GCC Viral Vectors and Plasmid DNA Manufacturing Market Analysis
19.11 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Analysis
19.12 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Analysis
20 Company Profiles
20.1 Competitive Landscape, 2022
20.2 Strategic Outlook
20.3 Amicus Therapeutics
20.3.1 Company Snapshot
20.3.2 Company Overview
20.3.3 Financial Analysis
20.3.3.1 Net Revenue, 2017-2022
20.3.3.2 R&D, 2017-2022
20.3.3.3 Regional Market Shares, 2022
20.3.4 Product Benchmarking
20.3.5 Strategic Outlook
20.4 Lonza Group Ltd.
20.4.1 Company Snapshot
20.4.2 Company Overview
20.4.3 Financial Analysis
20.4.3.1 Net Revenue, 2017-2022
20.4.3.2 R&D, 2017-2022
20.4.3.3 Regional Market Shares, 2022
20.4.4 Product Benchmarking
20.4.5 Strategic Outlook
20.5 Merck KGaA
20.5.1 Company Snapshot
20.5.2 Company Overview
20.5.3 Financial Analysis
20.5.3.1 Net Revenue, 2017-2022
20.5.3.2 R&D, 2017-2022
20.5.3.3 Regional Market Shares, 2022
20.5.4 Product Benchmarking
20.5.5 Strategic Outlook
20.6 uniQure N.V.
20.6.1 Company Snapshot
20.6.2 Company Overview
20.6.3 Financial Analysis
20.6.3.1 Net Revenue, 2017-2022
20.6.3.2 R&D, 2017-2022
20.6.3.3 Regional Market Shares, 2022
20.6.4 Product Benchmarking
20.6.5 Strategic Outlook
20.7 Catalent Inc.
20.7.1 Company Snapshot
20.7.2 Company Overview
20.7.3 Financial Analysis
20.7.3.1 Net Revenue, 2017-2022
20.7.3.2 Regional Market Shares, 2022
20.7.4 Product Benchmarking
20.7.5 Strategic Outlook
20.8 Thermo Fisher Scientific Inc.
20.8.1 Company Snapshot
20.8.2 Company Overview
20.8.3 Financial Analysis
20.8.3.1 Net Revenue, 2017-2022
20.8.3.2 R&D, 2017-2022
20.8.3.3 Regional Market Shares, 2022
20.8.4 Product Benchmarking
20.8.5 Strategic Outlook
20.9 Charles River Laboratories
20.9.1 Company Snapshot
20.9.2 Company Overview
20.9.3 Financial Analysis
20.9.3.1 Net Revenue, 2017-2022
20.9.3.2 Regional Market Shares, 2022
20.9.4 Product Benchmarking
20.9.5 Strategic Outlook
20.10 FUJIFILM Diosynth Biotechnologies
20.10.1 Company Snapshot
20.10.2 Company Overview
20.10.3 Product Benchmarking
20.10.4 Strategic Outlook
20.11 bluebird bio Inc.
20.11.1 Company Snapshot
20.11.2 Company Overview
20.11.3 Product Benchmarking
20.11.4 Strategic Outlook
20.12 Aldevron
20.12.1 Company Snapshot
20.12.2 Company Overview
20.12.3 Product Benchmarking
20.12.4 Strategic Outlook
20.13 Addgene
20.13.1 Company Snapshot
20.13.2 Company Overview
20.13.3 Product Benchmarking
20.14 Creative Biogene
20.14.1 Company Snapshot
20.14.2 Company Overview
20.14.3 Product Benchmarking
20.15 VIVEbiotech
20.15.1 Company Snapshot
20.15.2 Company Overview
20.15.3 Product Benchmarking
20.15.4 Strategic Outlook
20.16 Recipharm AB
20.16.1 Company Snapshot
20.16.2 Company Overview
20.16.3 Product Benchmarking
20.16.4 Strategic Outlook
20.17 Waisman Biomanufacturing
20.17.1 Company Snapshot
20.17.2 Company Overview
20.17.3 Product Benchmarking
20.17.4 Strategic Outlook
20.18 VGXI, Inc.
20.18.1 Company Snapshot
20.18.2 Company Overview
20.18.3 Product Benchmarking
20.18.4 Strategic Outlook
20.19 Batavia Biosciences B.V.
20.19.1 Company Snapshot
20.19.2 Company Overview
20.19.3 Product Benchmarking
20.19.4 Strategic Outlook
20.20 WuXi AppTec
20.20.1 Company Snapshot
20.20.2 Company Overview
20.20.3 Product Benchmarking
20.20.4 Strategic Outlook
20.21 ATUM
20.21.1 Company Snapshot
20.21.2 Company Overview
20.21.3 Product Benchmarking
20.21.4 Strategic Outlook
20.22 Altogen Biosystems
20.22.1 Company Snapshot
20.22.2 Company Overview
20.22.3 Product Benchmarking
20.23 GENEZEN
20.23.1 Company Snapshot
20.23.2 Company Overview
20.23.3 Product Benchmarking
20.23.4 Strategic Outlook
20.24 Yposkesi, Inc.
20.24.1 Company Snapshot
20.24.2 Company Overview
20.24.3 Product Benchmarking
20.24.4 Strategic Outlook
20.25 CEVEC Pharmaceuticals GmbH
20.25.1 Company Snapshot
20.25.2 Company Overview
20.25.3 Product Benchmarking
20.25.4 Strategic Outlook
20.26 Virovek
20.26.1 Company Snapshot
20.26.2 Company Overview
20.26.3 Product Benchmarking
20.26.4 Strategic Outlook
20.27 Advanced BioScience Laboratories, Inc (ABL)
20.27.1 Company Snapshot
20.27.2 Company Overview
20.27.3 Product Benchmarking
20.27.4 Strategic Outlook
20.28 Biovian Oy
20.28.1 Company Snapshot
20.28.2 Company Overview
20.28.3 Product Benchmarking
20.28.4 Strategic Outlook
20.29 BioNTech IMFS
20.29.1 Company Snapshot
20.29.2 Company Overview
20.29.3 Product Benchmarking
20.29.4 Strategic Outlook
21 Conclusion and Recommendations
21.1 Concluding Remarks from Visiongain
21.2 Recommendations for Market Players
List of Tables
Table 1 Viral Vectors and Plasmid DNA Manufacturing Market Snapshot, 2024 & 2034 (US$ Million, CAGR %)
Table 2 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "V" Shaped Recovery
Table 3 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "U" Shaped Recovery
Table 4 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "W" Shaped Recovery
Table 5 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024-2034 (US$ Million, AGR%, CAGR%): "L" Shaped Recovery
Table 6 CMOs Capacity for Viral Vector Manufacturing
Table 7 Cleanroom Suites Facilities
Table 8 Investments and Expansions in CMO/CDMO Facilities in the Cell and Gene Therapy Sector
Table 9 Addressing Challenges and Technological Solutions
Table 10 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 11 Adenovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 12 Retrovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 13 Plasmid DNA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 14 AAV Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 15 Lentivirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 16 Other Vaccine Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 17 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 18 Antisense RNAi Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 19 Bacterial Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 20 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 21 Vaccinology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 22 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 23 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 24 Genetic Disorders Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 25 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 26 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 27 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 28 Pharma and Biopharma Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 29 Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 30 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 31 Upstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 32 Downstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 33 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 34 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 35 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 36 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 37 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 38 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 39 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 40 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 41 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 42 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR %)
Table 43 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 44 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 45 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 46 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 47 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 48 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 49 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 50 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 51 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 52 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 53 Sweden Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 54 Switzerland Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 55 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 56 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 57 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 58 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 59 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 60 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 61 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 62 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 63 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 64 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 65 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 66 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 67 Singapore Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 68 Taiwan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 69 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 70 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 71 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 72 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 73 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 74 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 75 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 76 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 77 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 78 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 79 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 80 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 81 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 82 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 83 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 84 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast Workflow, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 85 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 86 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 87 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR%, CAGR%)
Table 88 Strategic Outlook
Table 89 Amicus Therapeutics: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 90 Amicus Therapeutics : Product Benchmarking
Table 91 AstraZeneca: Strategic Outlook
Table 92 Lonza Group Ltd.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 93 Lonza Group Ltd.: Product Benchmarking
Table 94 Lonza Group Ltd.: Strategic Outlook
Table 95 Merck KGaA: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 96 Merck KGaA: Product Benchmarking
Table 97 Merck: Strategic Outlook
Table 98 uniQure N.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 99 uniQure N.V. : Product Benchmarking
Table 100 uniQure N.V. : Strategic Outlook
Table 101 Catalent Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 102 Catalent Inc.: Product Benchmarking
Table 103 Catalent Inc.: Strategic Outlook
Table 104 Thermo Fisher Scientific Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 105 Thermo Fisher Scientific Inc.: Product Benchmarking
Table 106 Thermo Fisher Scientific Inc.: Strategic Outlook
Table 107 Charles River Laboratories: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 108 Charles River Laboratories: Product Benchmarking
Table 109 Charles River Laboratories International Inc: Strategic Outlook
Table 110 FUJIFILM Diosynth Biotechnologies: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 111 FUJIFILM Diosynth Biotechnologies: Product Benchmarking
Table 112 FUJIFILM Diosynth Biotechnologies: Strategic Outlook
Table 113 bluebird bio Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 114 bluebird bio Inc.: Product Benchmarking
Table 115 bluebird bio Inc.: Strategic Outlook
Table 116 Aldevron: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 117 Aldevron: Product Benchmarking
Table 118 Aldevron: Strategic Outlook
Table 119 Addgene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 120 Addgene: Product Benchmarking
Table 121 Creative Biogene: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 122 Creative Biogene: Product Benchmarking
Table 123 Vivebiotech: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 124 VIVEbiotech: Product Benchmarking
Table 125 VIVEbiotech: Strategic Outlook
Table 126 Recipharm AB: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 127 Recifarm AB: Product Benchmarking
Table 128 Recipharm AB: Strategic Outlook
Table 129 Waisman Biomanufacturing: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 130 Waisman Biomanufacturing: Product Benchmarking
Table 131 Waisman Biomanufacturing: Strategic Outlook
Table 132 VGXI, Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 133 VGXI, Inc. : Product Benchmarking
Table 134 VGXI, Inc.: Strategic Outlook
Table 135 Batavia Biosciences B.V.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 136 Batavia Biosciences B.V. : Product Benchmarking
Table 137 Batavia Biosciences B.V.: Strategic Outlook
Table 138 WuXi AppTec: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 139 Wuxi AppTec: Product Benchmarking
Table 140 Wuxi AppTec: Strategic Outlook
Table 141 ATUM: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 142 ATUM: Product Benchmarking
Table 143 ATUM: Strategic Outlook
Table 144 Altogen Biosystems: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 145 Altogen Biosystems: Product Benchmarking
Table 146 Genezen: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 147 Genezen: Product Benchmarking
Table 148 Genezen: Strategic Outlook
Table 149 Yposkesi, Inc: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 150 Yposkesi, Inc: Product Benchmarking
Table 151 Yposkesi, Inc: Strategic Outlook
Table 152 CEVEC Pharmaceuticals GmbH : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 153 CEVEC Pharmaceuticals GmbH : Product Benchmarking
Table 154 CEVEC Pharmaceuticals GmbH: Strategic Outlook
Table 155 Virovek: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 156 Virovek : Product Benchmarking
Table 157 Virovek: Strategic Outlook
Table 158 ABL Inc.: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 159 ABL Inc.: Product Benchmarking
Table 160 ABL Inc.: Strategic Outlook
Table 161 Biovian Oy: Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 162 Biovian Oy : Product Benchmarking
Table 163 Biovian Oy: Strategic Outlook
Table 164 BioNTech IMFS : Key Details, (CEO, HQ, Revenue, Founded, No. of Employees, Company Type, Website, Business Segment)
Table 165 BioNTech IMFS: Product Benchmarking
Table 166 BioNTech IMFS: Strategic Outlook
List of Figures
Figure 1 Viral Vectors and Plasmid DNA Manufacturing Market Segmentation
Figure 2 Viral Vectors and Plasmid DNA Manufacturing Market by Vector Type: Market Attractiveness Index
Figure 3 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
Figure 4 Viral Vectors and Plasmid DNA Manufacturing Market by End-use: Market Attractiveness Index
Figure 5 Viral Vectors and Plasmid DNA Manufacturing Market by Disease: Market Attractiveness Index
Figure 6 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
Figure 7 Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index by Region
Figure 8 Viral Vectors and Plasmid DNA Manufacturing Market: Market Dynamics
Figure 9 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): “V” Shaped Recovery
Figure 10 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): “U” Shaped Recovery
Figure 11 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): “W” Shaped Recovery
Figure 12 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %): “L” Shaped Recovery
Figure 13 Viral Vectors and Plasmid Manufacturing Market: Porter’s Five Forces Analysis
Figure 14 Viral Vectors and Plasmid Manufacturing Market: PEST Analysis
Figure 15 Viral Vectors and Plasmid DNA Manufacturing Market by Vector Type: Market Attractiveness Index
Figure 16 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
Figure 17 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024, 2029, 2034 (%)
Figure 18 Adenovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 19 Adenovirus Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 20 Retrovirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 21 Retrovirus Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 22 Plasmid DNA Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 23 Plasmid DNA Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 24 AAV Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 25 AAV Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 26 Lentivirus Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 27 Lentivirus Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 28 Other Vectors Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 29 Other Vectors Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 30 Viral Vectors and Plasmid DNA Manufacturing Market by Application: Market Attractiveness Index
Figure 31 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 32 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024, 2029, 2034 (%)
Figure 33 Antisense RNAi Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 34 Antisense RNAi Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 35 Gene Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 36 Gene Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 37 Cell Therapy Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 38 Cell Therapy Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 39 Vaccinology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 40 Vaccinology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 41 Viral Vectors and Plasmid DNA Manufacturing Market by Disease: Market Attractiveness Index
Figure 42 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 43 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024, 2029, 2034 (%)
Figure 44 Oncology Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 45 Oncology Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 46 Genetic Disorders Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 47 Genetic Disorders Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 48 Infectious Diseases Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 49 Infectious Diseases Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 50 Others Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 51 Others Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 52 Viral Vectors and Plasmid DNA Manufacturing Market by End-use: Market Attractiveness Index
Figure 53 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
Figure 54 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024, 2029, 2034 (%)
Figure 55 Pharma and Biopharma Companies Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 56 Pharma and Biopharma Companies Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 57 Research Institutes Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 58 Research Institutes Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 59 Viral Vectors and Plasmid DNA Manufacturing Market by Workflow: Market Attractiveness Index
Figure 60 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow, 2024-2034 (US$ Million, AGR %)
Figure 61 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024, 2029, 2034 (%)
Figure 62 Upstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 63 Upstream Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 64 Downstream Segment Market Forecast by Region, 2024-2034 (US$ Million, AGR %)
Figure 65 Downstream Segment Market Share Forecast by Region, 2024 & 2034 (%)
Figure 66 Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Region 2024 and 2034 (Revenue, CAGR%)
Figure 67 Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Region 2024, 2029, 2034 (%)
Figure 68 Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024-2034 (US$ Million, AGR %)
Figure 69 North America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 70 North America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 71 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 72 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
Figure 73 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
Figure 74 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
Figure 75 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 76 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
Figure 77 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
Figure 78 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
Figure 79 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 80 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 81 North America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
Figure 82 North America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
Figure 83 U.S. Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 84 Canada Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 85 Europe Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 86 Europe Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 87 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 88 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
Figure 89 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
Figure 90 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
Figure 91 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 92 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
Figure 93 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
Figure 94 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
Figure 95 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 96 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 97 Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
Figure 98 Europe Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
Figure 99 Germany Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 100 France Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 101 UK Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 102 Italy Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 103 Spain Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 104 Sweden Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 105 Switzerland Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 106 Rest of Europe Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 107 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 108 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 109 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 110 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
Figure 111 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
Figure 112 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
Figure 113 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 114 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
Figure 115 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
Figure 116 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
Figure 117 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease, 2024-2034 (US$ Million, AGR %)
Figure 118 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 119 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
Figure 120 Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
Figure 121 Japan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 122 China Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 123 India Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 124 Australia Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 125 South Korea Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 126 Singapore Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 127 Taiwan Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 128 Rest of Asia Pacific Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 129 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 130 Latin America Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 131 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 132 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
Figure 133 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
Figure 134 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
Figure 135 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 136 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
Figure 137 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
Figure 138 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by End-use, 2024 & 2034 (%)
Figure 139 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
Figure 140 Latin America Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
Figure 141 Brazil Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 142 Mexico Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 143 Argentina Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 144 Rest of Latin America Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 145 MEA Viral Vectors and Plasmid DNA Manufacturing Market Attractiveness Index
Figure 146 MEA Viral Vectors and Plasmid DNA Manufacturing Market by Region, 2024, 2029 & 2034 (US$ Million)
Figure 147 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Country, 2024-2034 (US$ Million, AGR %)
Figure 148 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Country, 2024 & 2034 (%)
Figure 149 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Vector Type, 2024-2034 (US$ Million, AGR %)
Figure 150 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Vector Type, 2024 & 2034 (%)
Figure 151 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Application, 2024-2034 (US$ Million, AGR %)
Figure 152 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
Figure 153 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by End-use, 2024-2034 (US$ Million, AGR %)
Figure 154 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Application, 2024 & 2034 (%)
Figure 155 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Disease 2024-2034 (US$ Million, AGR %)
Figure 156 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Disease, 2024 & 2034 (%)
Figure 157 MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast by Workflow 2024-2034 (US$ Million, AGR %)
Figure 158 MEA Viral Vectors and Plasmid DNA Manufacturing Market Share Forecast by Workflow, 2024 & 2034 (%)
Figure 159 GCC Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 160 South Africa Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 161 Rest of MEA Viral Vectors and Plasmid DNA Manufacturing Market Forecast, 2024-2034 (US$ Million, AGR %)
Figure 162 Amicus Therapeutics: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 163 Amicus Therapeutics: R&D, 2017-2022 (US$ Million, AGR%)
Figure 164 Amicus Therapeutics: Regional Market Shares, 2022
Figure 165 Lonza Group Ltd.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 166 Lonza Group Ltd.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 167 Lonza Group: Regional Market Shares, 2022
Figure 168 Merck KGaA: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 169 Merck KGaA: R&D, 2017-2022 (US$ Million, AGR%)
Figure 170 Merck KGaA: Regional Market Shares, 2022
Figure 171 uniQure N.V.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 172 uniQure N.V.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 173 uniQure N.V.: Net Revenue: Regional Market Shares, 2022
Figure 174 Catalent Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 175 Catalent Inc.: Regional Market Shares, 2022
Figure 176 Thermo Fisher Scientific Inc.: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 177 Thermo Fisher Scientific Inc.: R&D, 2017-2022 (US$ Million, AGR%)
Figure 178 Thermo Fisher Scientific Inc.: Regional Market Shares, 2022
Figure 179 Charles River Laboratories: Net Revenue, 2017-2022 (US$ Million, AGR%)
Figure 180 Charles River Laboratories International Inc: Regional Market Shares, 2022
List of Companies Profiled in the Report
Addgene
Advanced BioScience Laboratories, Inc. (ABL)
Aldevron
Altogen Biosystems
Amicus Therapeutics
ATUM
Batavia Biosciences B.V.
BioNTech IMFS
Biovian Oy
bluebird bio Inc.
Catalent Inc.
CEVEC Pharmaceuticals GmbH
Charles River Laboratories
Creative Biogene
FUJIFILM Diosynth Biotechnologies
GENEZEN
Lonza
Merck KGaA
Recipharm AB
Thermo Fisher Scientific Inc.
uniQure N.V.
VGXI Inc.
Virovek
VIVEbiotech
Waisman Biomanufacturing
WuXi AppTec
Yposkesi, Inc.
List of Other Companies Mentioned in the Report
Abeona Therapeutics
Anagram Therapeutics Inc.
AGC Biologics
Atamyo Therapeutics
Acucela
Adaptimmune Therapeutics
Arranta Bio
Bio Elpida
BioReliance
Bristol Myers Squibb
Bunyavax BV
Chimeron Bio
Curigin
Cytiva
CorEvitas, LLC
Evanoa Bioscience Inc.
Forge Biologics
Genenta
Genentech
GenIbet Biopharmaceuticals
Hanmi Pharmaceutical
Immunomic Therapeutics
Integrum Scientific, LLC.
Incannex
Integrated DNA Technologies, Inc. (IDT)
Inbiomed
Indiana University Vector Production Facility
Kite
Novartis
Phoenix Nest Inc.,
Promega Corporation
Remedium Bio
SK pharmteco
Takeda Pharmaceuticals
T-MAXIMUM
VIVEbiotech
Xpress Biologics
List of Associations Mentioned in the Report
Alliance for Regenerative Medicine
Bill & Melinda Gates Foundation
Coalition for Epidemic Preparedness Innovations (CEPI)
European Medicines Agency (EMA)
European Society of Gene and Cell Therapy
Food and Drug Administration
Health Canada
INADcure Foundation
Kobe University
Medicines and Healthcare products Regulatory Agency (MHRA)
National Center for Biotechnology Information
Tel Aviv University (TAU)
University of Oxford
University of Veterinary Medicine Hannover
University of Wisconsin–Madison
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
